WINTON GROUP Ltd Grows Position in Inspire Medical Systems, Inc. $INSP

Key Points

• WINTON GROUP Ltd increased its Inspire Medical Systems position by 790.8% in the second quarter, reaching 37,412 shares valued at approximately $1.67 million. Institutional investors collectively own 94.91% of the company.
• Analyst sentiment remains mixed, with ratings ranging from Strong Buy to Sell; the consensus rating is Hold with an average price target of $66.50.
• Inspire reported quarterly EPS of $0.14, exceeding the expected loss of $0.24, while revenue of $200.58 million surpassed estimates but declined 7.6% year over year.

WINTON GROUP Ltd boosted its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 790.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,412 shares of the company's stock after acquiring an additional 33,212 shares during the period. WINTON GROUP Ltd owned about 0.13% of Inspire Medical Systems worth $1,669,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in Inspire Medical Systems during the second quarter valued at approximately $211,341,000. Wellington Management Group LLP purchased a new stake in Inspire Medical Systems during the fourth quarter worth $203,929,000. California State Teachers Retirement System lifted its holdings in Inspire Medical Systems by 3,720.8% during the second quarter. California State Teachers Retirement System now owns 1,317,155 shares of the company's stock worth $58,758,000 after buying an additional 1,282,682 shares during the period. Deerfield Management Company L.P. boosted its position in Inspire Medical Systems by 648.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company's stock valued at $77,739,000 after acquiring an additional 907,694 shares in the last quarter. Finally, Morgan Stanley boosted its position in Inspire Medical Systems by 179.5% during the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company's stock valued at $116,188,000 after acquiring an additional 809,121 shares in the last quarter. Institutional investors own 94.91% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on INSP shares. Summit Redstone set a $39.00 price target on Inspire Medical Systems in a research report on Friday, May 22nd. Weiss Ratings downgraded Inspire Medical Systems from a "sell (d+)" rating to a "sell (d)" rating in a research report on Friday, September 4th. Bank of America lowered Inspire Medical Systems from a "neutral" rating to an "underperform" rating and set a $39.00 target price on the stock. in a research note on Friday, May 22nd. Robert W. Baird boosted their target price on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the stock a "neutral" rating in a report on Tuesday, August 4th. Finally, Mizuho increased their price target on shares of Inspire Medical Systems from $55.00 to $65.00 and gave the company an "outperform" rating in a research report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $66.50.

Insiders Place Their Bets

In other news, insider Jason Kelly sold 963 shares of the business's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $59.55, for a total transaction of $57,346.65. Following the sale, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.20% of the company's stock.

Inspire Medical Systems Trading Up 6.7%

Shares of INSP opened at $72.70 on Friday. Inspire Medical Systems, Inc. has a 12 month low of $38.91 and a 12 month high of $147.03. The stock has a fifty day moving average price of $57.11 and a 200-day moving average price of $52.65. The firm has a market cap of $2.10 billion, a PE ratio of 15.74, a P/E/G ratio of 5.55 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The firm had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. During the same period in the previous year, the business earned $0.45 EPS. The firm's revenue for the quarter was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, research analysts forecast that Inspire Medical Systems, Inc. will post 1.24 EPS for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc develops and commercializes medical devices for treating moderate to severe obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company's primary product is Inspire therapy, an implantable system designed for patients who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses a small implantable pulse generator, a breathing-sensing lead and a stimulation lead.

Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.